No

Antihypertensive Agent, Combination

Treatment of hypertension

C/D (2nd and 3rd trimesters)

The mechanism through which benazepril lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, benazepril has an antihypertensive effect even in patients with low-renin hypertension; amlodipine is a dihydropyridine calcium antagonist that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle; amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure

Absorption: Not influenced by the presence of food in the GI tract; food effects on absorption have not been studied

Amlodipine: 64% to 90%

Benazepril: 37%

Time to peak (plasma):

Amlodipine: 6-12 hours

Benazepril: 0.5-2 hours

Adults: Oral: 1 capsule daily

No information available to require special precautions

Calcium channel blockers (CCBs) cause gingival hyperplasia in approximately 1% of the patients. There have been fewer reports with amlodipine than with other CCBs. The hyperplasia will usually disappear with cessation of drug therapy. Consultation with physician is suggested.

See individual agents. Pregnancy/breast-feeding precautions: Inform prescriber if you are or intend to be pregnant. Consult prescriber if breast-feeding.

Capsule:

Amlodipine 5 mg and benazepril hydrochloride 10 mg

Amlodipine 5 mg and benazepril hydrochloride 20 mg

Wynn RL, "An Update on Calcium Channel Blocker-Induced Gingival Hyperplasia," Gen Dent, 1995, 43(3):218-22.

Wynn RL, "Calcium Channel Blockers and Gingival Hyperplasia," Gen Dent, 1991, 39(4):240-3.